• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour.

作者信息

Hernes Eivor, Fosså Sophie D, Skovlund Eva

机构信息

Department of Clinical Cancer Research, The Norwegian Radium Hospital, Montebello, Oslo, Norway.

出版信息

Acta Oncol. 2003;42(7):749-55. doi: 10.1080/02841860310014624.

DOI:10.1080/02841860310014624
PMID:14690161
Abstract

This retrospective study describes three clinically different groups of patients with symptomatic androgen-independent prostate cancer (AIPC) referred to palliative radiotherapy (RT): those with a symptomatic pelvic tumour and pelvis-confined disease (M0 P-RT: 35 patients), those with a symptomatic pelvic tumour and distant metastases (M + P-RT: 97 patients) and those with painful bone metastases (BM-RT: 193 patients). The study emphasises the need of a combined surgical and radiotherapeutic palliation in AIPC patients with symptomatic pelvic tumours. Median overall survival from time of palliative RT was 19, 9 and 8 months for M0 P-RT, M + P-RT and BM-RT patients, respectively (p < 0.001). The significantly prolonged natural course of P-RT patients without distant metastases has to be accounted for in clinical trials of AIPC patients in whom survival represents an endpoint. Furthermore, the optimal palliation regimens for P-RT patients are still to be defined.

摘要

相似文献

1
Androgen-independent prostate cancer--the clinical problem of a growing pelvic tumour.
Acta Oncol. 2003;42(7):749-55. doi: 10.1080/02841860310014624.
2
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.多西他赛、磷酸雌莫司汀和唑来膦酸联合治疗雄激素非依赖性转移性前列腺癌:疗效、安全性及临床获益评估
Urology. 2005 Jan;65(1):126-30. doi: 10.1016/j.urology.2004.08.041.
3
Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
BJU Int. 2000 Aug;86(3):240-7. doi: 10.1046/j.1464-410x.2000.00767.x.
4
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.局部晚期前列腺癌男性患者中短期雄激素抑制联合放疗与中期雄激素抑制联合放疗、联合或不联合唑来膦酸的比较(TROG 03.04 RADAR):一项开放标签、随机、3 期析因试验。
Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.
5
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.前列腺癌根治术和盆腔淋巴结清扫术后淋巴结阳性患者的即刻与延迟雄激素剥夺治疗
Lancet Oncol. 2006 Jun;7(6):472-9. doi: 10.1016/S1470-2045(06)70700-8.
6
The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.联合放射治疗和激素治疗在淋巴结阳性前列腺癌管理中的应用。
Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):673-80. doi: 10.1016/s0360-3016(97)00369-6.
7
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.评估调强放疗联合原位基因治疗加或不加激素治疗前列腺癌的I-II期试验——前列腺特异抗原反应及活检数据中期报告
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9. doi: 10.1016/j.ijrobp.2003.09.083.
8
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.一项针对高危前列腺癌进行两年雄激素抑制联合放疗并联合或不联合辅助化疗的3期试验:放射治疗肿瘤学组3期随机试验NRG肿瘤学RTOG 9902的最终结果
Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):294-302. doi: 10.1016/j.ijrobp.2015.05.024. Epub 2015 Jul 21.
9
Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.新辅助激素治疗后接受根治性前列腺切除术的临床局限性前列腺癌患者,实时逆转录聚合酶链反应检测盆腔淋巴结微转移的意义。
BJU Int. 2007 Feb;99(2):315-20. doi: 10.1111/j.1464-410X.2006.06622.x. Epub 2006 Nov 28.
10
Is there a "curative" role of radiotherapy for clinically localized hormone refractory prostate cancer?对于临床局限性激素难治性前列腺癌,放射治疗是否具有“治愈”作用?
Am J Clin Oncol. 2004 Jun;27(3):264-8. doi: 10.1097/01.coc.0000092565.46506.bc.

引用本文的文献

1
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated?转移性前列腺癌患者的局部和全身治疗:原发肿瘤是否应接受治疗?
Curr Urol Rep. 2005 May;6(3):183-9. doi: 10.1007/s11934-005-0006-5.
2
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.雄激素非依赖期之前及期间前列腺癌中表皮生长因子受体家族的表达
Br J Cancer. 2004 Jan 26;90(2):449-54. doi: 10.1038/sj.bjc.6601536.